CD8A and neoplasm: Moreover, simultaneous NY-ESO-1-specific antibody and CD8+ responses correlate with superior outcomes in immunotherapy, suggesting that once tumor antigen is removed, falling antibody titers accompany a shift from chronic antigenic stimulation to effective effector-T-cell surveillance [34].